Literature DB >> 12639483

Comprehensive systematic surveillance for adverse effects of anthrax vaccine adsorbed, US Armed Forces, 1998-2000.

Jeffrey L Lange1, Sandra E Lesikar, Mark V Rubertone, John F Brundage.   

Abstract

Routine vaccinations of US military personnel with Anthrax Vaccine Adsorbed began in 1998. To systematically identify clinical diagnoses reported more frequently after vaccination than before, all military personnel were retrospectively assigned to pre- or post-vaccination cohorts. Cohort assignments were based on vaccination statuses each day of the 3-year surveillance period. For each cohort, rates of hospitalizations and ambulatory visits for 843 specific diagnoses were calculated using data in a public health surveillance system. Compared to the pre-vaccination cohort, the post-vaccination cohort had statistically higher rates of hospitalizations for 17 diagnoses, of ambulatory visits for 34 diagnoses, and in both clinical settings for one diagnosis (malaria). After accounting for systematic differences in coding/reporting and residual confounding, the number and nature of clinical diagnoses more frequent after anthrax vaccination than before were consistent with expectations due to random variation. This surveillance suggests that Anthrax Vaccine Adsorbed has few, if any, clinically significant adverse effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639483     DOI: 10.1016/s0264-410x(02)00723-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Health concerns in UK Armed Forces personnel.

Authors:  Dominic Murphy; Neil Greenberg; Duncan Bland
Journal:  J R Soc Med       Date:  2009-04       Impact factor: 5.344

2.  Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Authors:  Tracy Pondo; Charles E Rose; Stacey W Martin; Wendy A Keitel; Harry L Keyserling; Janiine Babcock; Scott Parker; Robert M Jacobson; Gregory A Poland; Michael M McNeil
Journal:  Vaccine       Date:  2014-04-24       Impact factor: 3.641

3.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

Review 4.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01

5.  Identification of peptide sequences as a measure of Anthrax vaccine stability during storage.

Authors:  Gail Whiting; Jun X Wheeler; Sjoerd Rijpkema
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 6.  Anthrax vaccines.

Authors:  Miroslav Splino; Jiri Patocka; Roman Prymula; Roman Chlibek
Journal:  Ann Saudi Med       Date:  2005 Mar-Apr       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.